首页|期刊导航|河南中医|中药复方防治放射性肺损伤研究进展

中药复方防治放射性肺损伤研究进展OA

Research Progress on Chinese Medicinal Compound Formulas in the Prevention and Treatment of Radiation Induced Lung Injury

中文摘要英文摘要

放射性肺损伤(radiation-induced lung injury,RILI)是胸部肿瘤放疗后常见的严重并发症,早期表现为放射性肺炎,晚期可进展为不可逆的放射性肺纤维化,严重影响患者生存质量与预后.目前,西医以糖皮质激素和对症支持为主,难以阻断纤维化进程,缺乏有效治疗手段.中药复方凭借多靶点、多通路协同调节优势,在 RILI 防治中展现出独特潜力.本文系统梳理中药复方治疗 RILI 的研究进展发现,中药复方可通过调控 TGF-β/Smad、NF-κB、Wnt/β-catenin、Nrf2/HO-1 及 p38 MAPK等信号通路,抑制炎症级联反应、氧化应激与上皮-间充质转化,减轻胶原沉积,进而发挥调节机体免疫、改善肺功能、延缓纤维化进程的作用,且可提高患者生活质量,安全性良好.然而,当前研究仍存在证型标准不统一、样本量小、机制研究碎片化、复方物质基础不清、作用靶点不明确等问题.未来应建立统一诊断与疗效评价标准,开展多中心、大样本、随机对照试验;探索个体化防治策略;结合多组学与类器官技术,明确药效物质基础与作用靶点,推动中药复方在 RILI 管理中的循证化与国际化发展.

Radiation induced lung injury(RILI)is a common and severe complication following radiotherapy for thoracic malignancies.Its early manifestation is radiation pneumonitis,which may progress to irreversible radiation pulmonary fibrosis at the late stage,seriously impairing patients' quality of life and prognosis.At present,Western medicine mainly adopts glucocorticoids and symptomatic supportive therapies,which can hardly block the fibrotic process,and effective therapeutic approaches remain insufficient.Benefiting from the ad-vantages of multi-target and multi-pathway synergistic regulation,Chinese medicinal compound formulas have demonstrated unique po-tential in the prevention and treatment of RILI.This paper systematically reviews the research progress of Chinese medicinal compound formulas for RILI.Existing evidence indicates that such formulas can suppress inflammatory cascade responses,oxidative stress and epi-thelial-mesenchymal transition,and alleviate collagen deposition by modulating signaling pathways including TGF-β/Smad,NF-κB,Wnt/β-catenin,Nrf2/HO-1 and p38 MAPK.Consequently,they exert effects on regulating host immunity,improving pulmonary function and retarding fibrotic progression,which can improve patients' quality of life,with good safety.Nevertheless,current studies are confront-ed with several limitations,including inconsistent syndrome differentiation criteria,small sample sizes,fragmented mechanistic investiga-tions,ambiguous material basis of compounds,and undefined action targets.Therefore,in future research,unified diagnostic and efficacy evaluation criteria should be established,and multi-center,large-sample randomized controlled trials ought to be carried out.Individual-ized prevention treatment strategies should be explored.Multi-omics and organoid technologies should be integrated to clarify the phar-macodynamic material basis and molecular targets,so as to promote the evidence-based and international development of Chinese medic-inal compound formulas for RILI management.

程权;傅华洲

杭州市第一人民医院,浙江 杭州 310006杭州市第一人民医院,浙江 杭州 310006

医药卫生

放射性肺损伤中药复方放射性肺纤维化炎症反应氧化应激上皮-间充质转化

radiation induced lung injuryChinese medicinal compound formulasradiation pulmonary fibrosisinflammatory responseoxidative streeepithelial-mesenchymal transition

《河南中医》 2026 (10)

1487-1494,8

国家中医药管理局第七批全国老中医药专家学术经验继承工作项目{国中医药人教函[2022]76号}浙江省名老中医专家传承工作室建设项目(GZS2020029)浙江省医药卫生科技计划项目(2024KY1323)浙江省中医药科技计划项目(2026ZL0597)

10.16367/j.issn.1003-5028.2026.10.0242

评论